SCHEMBL2370876

SCHEMBL2370876

ClC(Cl)Oc1ccnnn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28785800 0.78 GABRA1 (0.36)
SCHEMBL8568961 0.75
SCHEMBL26556 0.74 MEN1 (0.31)
SCHEMBL5187237 0.74 BDKRB2 (0.30)
SCHEMBL134811 0.72
Hydrochloric Acid SCHEMBL9616927 0.70
SCHEMBL3172913 0.70
SCHEMBL9185014 0.70
SCHEMBL7111906 0.70
SCHEMBL27691808 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2547645-B1 PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV JANSSEN PHARMACEUTICALS INC (US) 2018-07-04 EP claimed
EP-3239129-A1 PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV Janssen Pharmaceuticals, Inc. (US) 2017-11-01 EP claimed
US-9586893-B2 Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV Janssen Pharmaceuticals (US) 2017-03-07 US claimed
US-9227965-B2 Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV Janssen Pharmaceuticals, Inc. (US) 2016-01-05 US claimed
US-20140228574-A1 Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV JANSSEN PHARMACEUTICA NV (BE) 2014-08-14 US claimed
EP-2758386-A1 PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV Janssen Pharmaceuticals, Inc. (US) 2014-07-30 EP claimed
WO-2013041655-A1 PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV Janssen Pharmaceuticals, Inc. (US) 2013-03-28 WO claimed
EP-2547645-A1 PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV Janssen Pharmaceuticals, Inc. (US) 2013-01-23 EP claimed
US-20130005976-A1 Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV Janssen Pharmaceuticals, Inc. (US) 2013-01-03 US claimed
WO-2011113859-A1 PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) 2011-09-22 WO claimed
EP-4359391-B1 TRIAZINE DERIVATIVES FOR THE TREATMENT OF TUMOURS AND NEURODEGENERATIVE DISORDERS UNIV DEGLI STUDI MILANO (IT) 2026-03-18 EP disclosed
US-20240327387-A1 TRIAZINE DERIVATIVES FOR THE TREATMENT OF TUMOURS AND NEURODEGENERATIVE DISORDERS UNIVERSITA DEGLI STUDI DI MILANO (IT) 2024-10-03 US disclosed
EP-3604305-B1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF WAKUNAGA PHARMA CO LTD (JP) 2024-08-28 EP disclosed
EP-4359391-A1 TRIAZINE DERIVATIVES FOR THE TREATMENT OF TUMOURS AND NEURODEGENERATIVE DISORDERS UNIVERSITA' DEGLI STUDI DI MILANO (IT) 2024-05-01 EP disclosed
CN-110520422-B Novel pyridonecarboxylic acid derivative or salt thereof 涌永制药株式会社 2023-09-05 CN disclosed
WO-2005042588-A1 CELLULOSE DERIVATIVE LENZING AKTIENGESELLSCHAFT (AT) 2005-05-12 WO disclosed
US-4778888-A Boron containing 1,3,5-triazines W. R. GRACE & CO. (US) 1988-10-18 US disclosed
EP-0135381-B1 REACTIVE DYES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1987-01-28 EP disclosed
US-4562251-A Agarose derivatives of amino phenyl boronic acid AMICON CORPORATION (US) 1985-12-31 US disclosed
EP-0135381-A1 Reactive dyes IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1985-03-27 EP disclosed